OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017

Via: OncoMed

REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.

Among the presentations will be three posters detailing preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology therapeutic candidate.  These will be the first data that the company has shared publicly for its anti-TIGIT antibody program.  New data will also be presented on biomarker research associated with the Phase 1b portion of OncoMed's tarextumab (anti-Notch2/3, OMP-59R5) clinical trial in small cell lung cancer and OncoMed's preclinical GITRL-Fc trimer (OMP-336B11) program.  In addition, xenograft data will be presented for anti-RSPO3 (OMP-131R10) in combination with taxane chemotherapy in colorectal cancer.

Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=1015497